Evidence map›Paper›PMID 34791825›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022

Smad3 Promotes Cancer-Associated Fibroblasts Generation via Macrophage-Myofibroblast Transition.

Philip Chiu-Tsun Tang, Jeff Yat-Fai Chung, Vivian Wei-Wen Xue, Jun Xiao, Xiao-Ming Meng, Xiao-Ru Huang, Shuang Zhou, Alex Siu-Wing Chan, Anna Chi-Man Tsang, Alfred Sze-Lok Cheng and 6 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 178 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Multi-omics reveals a novel Cxcr4Clinical and translational medicine · 2026
    Article
  11. Article
  12. Macrophage Extracellular Traps in Immunity and Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Philip Chiu-Tsun TangDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0002-1768-1127
Jeff Yat-Fai ChungDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Vivian Wei-Wen XueDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Jun XiaoDepartment of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Xiao-Ming MengSchool of Pharmacy, Anhui Medical University, An Hui, China.
Xiao-Ru HuangDepartment of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Shuang ZhouDepartment of Histology and Embryology, Tongji University School of Medicine, Tongji University Cancer Institute, Shanghai, China.
Alex Siu-Wing ChanDepartment of Applied Social Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong, China.
Anna Chi-Man TsangDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Alfred Sze-Lok ChengSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Tin-Lap LeeReproduction, Development and Endocrinology Program, School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Kam-Tong LeungDepartment of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Eric W-F LamSun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China.
Ka-Fai ToDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Patrick Ming-Kuen TangDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Hui-Yao LanDepartment of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Chinese University of Hong Kong · HKAnhui Medical University · CNHong Kong Polytechnic University · HKSun Yat-sen University · CNTongji University · CN

Funding

Direct Grant for Research CUHK 4054386Direct Grant for Research CUHK 4054440Faculty Innovation Award 4620528Innovation and Technology Fund of Hong Kong ITS/068/18Lui Che Woo Institute of Innovative Medicine CARE programResearch Grants Council of Hong Kong 14104019Research Grants Council of Hong Kong 14106518Research Grants Council of Hong Kong 14111019Research Grants Council of Hong Kong 14111720Research Grants Council of Hong Kong 14117418Research Grants Council of Hong Kong 14121816Research Grants Council of Hong Kong C7018-16GThe Guangdong-Hong Kong-Macao-Joint Labs Program from Guangdong Science and Technology 2019B121205005
6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAFs) are important in tumor microenvironment (TME) driven cancer progression. However, CAFs are heterogeneous and still largely underdefined, better understanding their origins will identify new therapeutic strategies for cancer. Here, the authors discovered a new role of macrophage-myofibroblast transition (MMT) in cancer for de novo generating protumoral CAFs by resolving the transcriptome dynamics of tumor-associated macrophages (TAM) with single-cell resolution. MMT cells (MMTs) are observed in non-small-cell lung carcinoma (NSCLC) associated with CAF abundance and patient mortality. By fate-mapping study, RNA velocity, and pseudotime analysis, existence of novel macrophage-lineage-derived CAF subset in the TME of Lewis lung carcinoma (LLC) model is confirmed, which is directly transited via MMT from M2-TAM in vivo and bone-marrow-derived macrophages (BMDM) in vitro. Adoptive transfer of BMDM-derived MMTs markedly promote CAF formation in LLC-bearing mice. Mechanistically, a Smad3-centric regulatory network is upregulated in the MMTs of NSCLC, where chromatin immunoprecipitation sequencing(ChIP-seq) detects a significant enrichment of Smad3 binding on fibroblast differentiation genes in the macrophage-lineage cells in LLC-tumor. More importantly, macrophage-specific deletion and pharmaceutical inhibition of Smad3 effectively block MMT, therefore, suppressing the CAF formation and cancer progression in vivo. Thus, MMT may represent a novel therapeutic target of CAF for cancer immunotherapy.

Indexed as

Adenocarcinoma of LungAnimalsCancer-Associated FibroblastsCell Line, TumorCell ProliferationDisease Models, AnimalLung NeoplasmsMacrophagesMiceMice, Inbred C57BLMice, Inbred NODMice, NudeMice, SCIDMyofibroblastsSignal TransductionSmad3 ProteinSmad3 ProteinSmad3 protein, mousecancer-associated fibroblastsmacrophage-myofibroblast transitionSmad3tumor-associated macrophagestumor microenvironment

Identifiers

PMID34791825
PMCPMC8728853
OpenAlexW3214347340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.